Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 2

Conditions

Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1

Interventions

venetoclax 33fludarabine 32Cyclophosphamide 31Azacitidine 29Specimen Handling 27Biopsy 19Cytarabine 18fludarabine phosphate 15Whole-Body Irradiation 15Stem Cell Transplantation 15Decitabine 15ruxolitinib 14Tacrolimus 14Melphalan 14Busulfan 14Mycophenolic Acid 13asciminib 10Injections 10decitabine and cedazuridine drug combination 8Thiotepa 8Methotrexate 8Hematopoietic Stem Cell Transplantation 8X-Rays 7Granulocyte Colony-Stimulating Factor 7Magnetic Resonance Spectroscopy 6Idarubicin 6Filgrastim 6Cyclosporine 6Blood Specimen Collection 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Liposomes × Myeloid × Clear all
NCT05554406 2026-06-05

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
335 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡